Core Viewpoint - The company aims to enhance its sustainable competitive advantage through comprehensive value chain reforms, despite facing challenges in revenue and profit due to new store openings and goodwill impairment losses [1]. Group 1: Financial Performance - In 2024, the company achieved a revenue of 22.358 billion yuan, a slight decrease of 0.36% year-on-year, while the net profit attributable to shareholders was 519 million yuan, down 44.13% [1]. - The decline in net profit is attributed to the increase in the number of new stores, which are still in the performance growth phase, and the company's recognition of goodwill impairment losses [1]. Group 2: Industry Trends and Strategy - The pharmaceutical retail industry is undergoing significant transformation, shifting from rapid expansion to a phase of differentiation and consolidation [1]. - In the first quarter of 2025, the company reported a net decrease in stores, with 211 new stores opened and 236 closed, resulting in a total reduction of 25 stores [1]. - The company plans to open 1,000 stores in 2025, primarily focusing on franchise stores and converting existing stores to franchises, while also pursuing strategic acquisitions in advantageous markets [1]. Group 3: Compliance and Ecosystem Development - The company emphasizes strengthening its compliance system and self-inspection mechanisms to ensure compliant operations, aiming to enhance store operational quality [2]. - The focus is on developing franchise and alliance businesses to integrate industry resources and build an ecosystem with small and medium-sized pharmacies, aiming to capture opportunities during the industry consolidation phase and increase market share [2]. Group 4: R&D and AI Initiatives - The company has been recognized as a technology center since 2011 and allocates approximately 0.6% of its total revenue annually for R&D, focusing on product and technology development [3]. - The company has developed over 70 self-researched business system products and obtained 102 software copyrights, supporting efficient business operations [3]. - An AI application strategy committee has been established to ensure the implementation of AI initiatives across various business areas, including the development of multiple generative dialogue assistants for different scenarios [3]. Group 5: Future Outlook - The company envisions a transformation from a single "pharmaceutical sales terminal" to a "comprehensive health service complex," aiming to meet evolving consumer health demands [3]. - The strategy includes deepening professional pharmaceutical services, enhancing prescription outsourcing capabilities, and expanding diverse service scenarios through physical pharmacies to create a health community ecosystem [3].